Workflow
超募资金
icon
Search documents
破发连亏股杰美特7名股东拟减持 2020年上市超募7.7亿
Zhong Guo Jing Ji Wang· 2025-08-06 04:13
Core Viewpoint - The company, Jiemite (300868.SZ), announced a share reduction plan involving several shareholders, which may impact the stock's market performance but will not change the company's control or significantly affect its ongoing operations [1][4]. Shareholder Reduction Plans - Huang Xin, holding 7,674,336 shares (6% of total shares), plans to reduce his holdings by 1,240,000 shares (0.978%) within three months after the announcement [1]. - Yang Shaoxu, with 415,500 shares (0.325%), intends to reduce his holdings by 415,500 shares (0.328%) in the same timeframe [1]. - Liu Hui, holding 6,900 shares (0.005%), plans to reduce by 6,900 shares (0.005%) [2]. - Li Yun, with 1,039 shares (0.001%), aims to reduce by 1,039 shares (0.001%) [2]. - Bian Erli, holding 18,397 shares (0.014%), plans to reduce by 18,397 shares (0.015%) [2]. - Chen Guangping, with 215,000 shares (0.168%), intends to reduce by 215,000 shares (0.170%) [3]. - Liu Shuwei, holding 34,297 shares (0.027%), plans to reduce by 8,500 shares (0.007%) [3]. - In total, the seven shareholders hold 8,365,469 shares and plan to reduce 1,905,336 shares, accounting for 1.504% of total shares [4][5]. Financial Performance - Jiemite's financial performance has shown fluctuations, with net profits for the years 2021 to 2024 being -116 million, -91.62 million, 707,000, and 7.07 million respectively [7]. - The company's revenue for 2023 was approximately 676.48 million, a decrease of 5.93% from 2022 [8]. - The net profit attributable to shareholders for 2023 was -91.62 million, while the net profit excluding non-recurring items was 133.35 million, indicating a significant recovery from previous losses [8]. - In the first quarter of 2025, the company reported a revenue of 150 million, a decline of 29.10% year-on-year, with a net profit of -3.66 million [9].
破发连亏股杰美特7名股东拟减持 2020年上市超募7.7亿
Zhong Guo Jing Ji Wang· 2025-08-06 03:33
Core Viewpoint - The company Jiemite (300868.SZ) announced a share reduction plan involving several shareholders, which will not affect the company's control or ongoing operations significantly [1][4][5]. Shareholder Reduction Plans - Shareholder Huang Xin plans to reduce holdings by 1,240,000 shares, representing 0.978% of the total shares after excluding repurchased shares [1][4]. - Shareholder Yang Shaoxu intends to reduce holdings by 415,500 shares, accounting for 0.328% of the total shares after excluding repurchased shares [1][2]. - Other shareholders, including Liu Hui, Li Yun, Bian Erli, Chen Guangping, and Liu Shuwei, also have plans to reduce their holdings, with total planned reductions amounting to 1,905,336 shares, or 1.504% of the total shares [4][5]. Financial Performance - Jiemite's financial performance has shown fluctuations, with net profits for the years 2021 to 2024 being 28.22 million, -116 million, -91.62 million, and 707,000 respectively [7]. - The company's revenue for 2023 was approximately 676.48 million, a decrease of 5.93% from 2022 [8]. - In 2024, the company expects a revenue increase to approximately 761.64 million, reflecting a 12.59% growth compared to 2023 [9]. Company Background - Jiemite was listed on the Shenzhen Stock Exchange on August 24, 2020, with an initial public offering price of 41.26 yuan per share, raising a net amount of approximately 118.97 million yuan [6]. - The company has faced challenges, with its stock currently trading below its initial offering price, indicating a state of underperformance [6].
索辰科技跌2.8% 2023年上市超募13亿国泰海通保荐
Zhong Guo Jing Ji Wang· 2025-07-24 08:58
Group 1 - The core viewpoint of the news is that Suochen Technology (688507.SH) is currently experiencing a decline in stock price, with a closing price of 85.50 yuan and a drop of 2.8%, indicating a state of being below its initial public offering price [1] - Suochen Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 18, 2023, with an issuance of 10,333,400 shares at a price of 245.56 yuan per share [1] - The total amount raised from the initial public offering was 253,746.97 million yuan, with a net amount of 231,574.91 million yuan, exceeding the original plan by 134,684.55 million yuan [1] Group 2 - The total issuance costs for Suochen Technology's IPO amounted to 22,172.06 million yuan (excluding tax), with underwriting fees accounting for 19,231.02 million yuan [2] - The company announced a cash dividend of 0.15 yuan per share (including tax) and a capital reserve increase of 0.48 shares for every share held, resulting in a total distribution of 6,200,010 yuan in cash dividends and an increase of 19,840,032 shares, raising the total share capital to 61,173,432 shares [2] - For the 2023 annual profit distribution, the company plans to distribute a cash dividend of 3.80 yuan for every 10 shares (including tax) and a capital reserve increase of 4.60 shares for every 10 shares, with the record date set for June 18, 2024 [2]
维远股份上半年预亏去年净利降 2021上市超募20亿元
Zhong Guo Jing Ji Wang· 2025-07-24 06:21
Core Viewpoint - Viyuan Co., Ltd. (维远股份) has announced a significant decline in expected net profit for the first half of 2025, projecting a loss between 175 million to 165 million yuan, compared to a profit of 35.73 million yuan in the same period last year [1] Financial Performance Summary - In 2024, Viyuan Co., Ltd. reported operating revenue of 9.52 billion yuan, representing a year-on-year increase of 35.06% [3] - The net profit attributable to shareholders decreased by 42.62% to 565.89 million yuan, down from 98.62 million yuan in 2023 [3] - The net profit after deducting non-recurring gains and losses was 453.11 million yuan, a decline of 36.85% compared to 71.75 million yuan in the previous year [3] - The net cash flow from operating activities increased by 49.52% to 918.53 million yuan, compared to 613.86 million yuan in 2023 [3] Initial Public Offering (IPO) Details - Viyuan Co., Ltd. raised a total of 4.065 billion yuan through its IPO, with a net amount of 3.88 billion yuan after deducting issuance costs [4] - The final net fundraising amount exceeded the original plan by 2 billion yuan, and the number of investment projects increased by one [4] - The IPO was conducted on September 15, 2021, with an issuance price of 29.56 yuan per share, and the underwriting was managed by CITIC Securities [4]
诚达药业跌13.12% 2022年上市超募11亿光大证券保荐
Zhong Guo Jing Ji Wang· 2025-07-23 08:44
Group 1 - The stock price of Chengda Pharmaceutical (301201.SZ) fell by 13.12% to 27.62 yuan as of the close on July 23, 2023 [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on January 20, 2022, with an initial public offering (IPO) of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest stock price recorded on the first day of trading was 188.00 yuan, indicating a significant decline since then, as the stock is currently in a state of "breaking" [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original planned amount by 1,108.17 million yuan, which was initially set at 513.28 million yuan for various projects and working capital [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [1] Group 3 - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 6 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for July 6, 2023, and the ex-dividend date was July 7, 2023 [2]
凯尔达上半年扣非亏损 2021上市超募5亿申万宏源保荐
Zhong Guo Jing Ji Wang· 2025-07-21 07:51
Group 1 - The company Kailda (688255.SH) has disclosed a voluntary announcement regarding its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of between 1.97 million and 2.56 million yuan, a decrease of 21.54 million to 20.95 million yuan compared to the same period last year, representing a year-on-year decline of 91.62% to 89.11% [1] - The company anticipates a net profit attributable to shareholders after deducting non-recurring gains and losses to be between -3.13 million and -2.54 million yuan, a decrease of 21.86 million to 21.27 million yuan compared to the same period last year, indicating a year-on-year decline of 116.71% to 113.56% [1] Group 2 - Kailda's initial public offering raised a total of 924 million yuan, with a net amount of 835 million yuan, exceeding the original plan by 518 million yuan [2] - The company planned to raise 317 million yuan for projects including the construction of an intelligent welding robot production line and an assembly testing laboratory, as well as to supplement working capital [2] - The total issuance costs for the IPO amounted to 88.51 million yuan, with the underwriting fees for the sponsor, Shenwan Hongyuan Securities, totaling 60.99 million yuan [2]
精智达股东2个月减持套现7306万 2023年上市超募3.9亿
Zhong Guo Jing Ji Wang· 2025-07-17 03:42
Core Viewpoint - The company, Jingzhida (688627.SH), announced the completion of a share reduction plan by its major shareholders, which involved a total reduction of 939,607 shares, representing 1% of the company's total share capital [1][3][5]. Shareholder Reduction Details - The shareholders involved in the reduction are Shenzhen Yuanchuangli Qingyuan Venture Capital Partnership, Changzhou Qingyuan Angel Venture Capital Partnership, Suzhou Xinlin Phase II Venture Capital, and Shanghai Lihua Qingyuan Venture Capital, collectively holding 7,094,655 shares, or 7.55% of the total shares [1][2]. - The reduction was executed through centralized bidding from April 28, 2025, to June 23, 2025, with a total reduction of 939,607 shares at a price range of 71.38 to 83.30 CNY per share, amounting to a total of 73,060,503.64 CNY [3][4]. Current Shareholding Status - After the reduction, the remaining shares held by the shareholders are 6,155,048, which is 6.55% of the total share capital [5]. - The original plan allowed for a maximum reduction of 940,118 shares, indicating that the plan was nearly fully executed with only 511 shares remaining untransacted [5]. Company IPO and Fundraising - Jingzhida was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 18, 2023, with an initial public offering of 23,502,939 shares at a price of 46.77 CNY per share, raising a total of 109,923.25 million CNY [5]. - The net proceeds from the offering, after deducting issuance costs, amounted to 98,656.46 million CNY, exceeding the original fundraising target by 38,656.46 million CNY [5]. Underwriter Participation - The underwriter, CITIC Securities, participated in the offering with a follow-on investment of approximately 4% of the total shares issued, amounting to 940,118 shares, with an investment of 43,969,318.86 CNY, subject to a 24-month lock-up period [6].
破发股三元生物股东拟减持 2022年上市即巅峰超募26亿
Zhong Guo Jing Ji Wang· 2025-07-11 03:35
Group 1 - The core point of the news is that Shandong Luxin Qisheng Investment Management Co., Ltd. plans to reduce its holdings in Sanyuan Bio by up to 6 million shares within a specified timeframe, which represents 3% of the total share capital after excluding shares held in the company's repurchase account [1] - The reduction will occur through both centralized bidding and block trading, with a maximum of 2 million shares (1% of total share capital) to be sold via centralized bidding and 4 million shares (2% of total share capital) through block trading [1] Group 2 - Sanyuan Bio was listed on the Shenzhen Stock Exchange's ChiNext board on February 10, 2022, with an initial public offering of 33.721 million shares at a price of 109.30 yuan per share, raising a total of 3.686 billion yuan [2] - The company’s shares reached a peak price of 146.00 yuan on the first day of trading but are currently in a state of decline [2] - The net proceeds from the IPO amounted to 3.547 billion yuan, exceeding the original fundraising target of 900 million yuan by 2.647 billion yuan [2] Group 3 - The total issuance costs for Sanyuan Bio's IPO were 139 million yuan, with underwriting fees accounting for 121 million yuan [3] - In June 2022, the company announced a dividend distribution plan for the 2021 fiscal year, distributing 10 yuan in cash per 10 shares and a bonus of 5 shares for every 10 shares held, increasing the total share capital from 135 million to 202 million shares [3]
仲景食品控股股东套现4124万元 上市即巅峰超募4亿元
Zhong Guo Jing Ji Wang· 2025-07-07 05:11
Core Viewpoint - The announcement details the share reduction by the controlling shareholder of Zhongjing Food, indicating a planned reduction of up to 4,380,000 shares, which is 3% of the total share capital, and highlights the recent shareholding changes and the company's financial background [1][2]. Group 1: Shareholding Changes - The controlling shareholder, Henan Wanshi Holdings Co., Ltd., reduced its shareholding from 38.75% to 37.80%, amounting to a decrease of 1,378,910 shares, which is a reduction of 0.94% [1][2]. - The weighted average price of Zhongjing Food's shares during the reduction period (May 28 to July 3, 2025) was 29.91 yuan, resulting in a total reduction amount of 41.24 million yuan [1]. Group 2: Company Background - Zhongjing Food was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 23, 2020, with a total public offering of 25 million shares, accounting for 25% of the total shares post-issue [2]. - The company raised a total of 993.5 million yuan, with a net amount of 912.75 million yuan after deducting issuance costs, exceeding the original fundraising plan by 420.75 million yuan [3]. - The funds raised are intended for various projects, including the production line for seasoning sauces and the construction of seasoning ingredient production lines [3]. Group 3: Financial Information - The issuance costs for Zhongjing Food amounted to 80.75 million yuan, with the underwriting fees to Guojin Securities totaling 67.50 million yuan [4]. - The company announced a stock bonus of 4.6 shares for every 10 shares held, along with a pre-tax dividend of 10 yuan, with the record date set for May 13, 2024 [4].
金凯生科上市超募3亿次年扣非净利降9成 中信建投保荐
Zhong Guo Jing Ji Wang· 2025-07-07 03:16
Group 1 - The core viewpoint of the articles highlights the financial performance of Jinkai Biotechnology, showcasing significant growth in Q1 2025 compared to the previous year, despite a decline in 2024 [1] - In Q1 2025, the company achieved operating revenue of 176 million yuan, a year-on-year increase of 41.83%, and a net profit attributable to shareholders of 47.42 million yuan, up 183.24% [1] - For the year 2024, the company reported operating revenue of 497 million yuan, a decrease of 35.19%, and a net profit attributable to shareholders of 38.61 million yuan, down 77.76% [1] Group 2 - Jinkai Biotechnology raised a total of 1.22 billion yuan from its initial public offering, with a net amount of approximately 1.11 billion yuan after deducting issuance costs, exceeding the original plan by 310 million yuan [2] - The company plans to use the raised funds for pharmaceutical intermediates, high-end pharmaceutical products, and to supplement working capital [2] - The annual equity distribution plan for 2023 includes a cash dividend of 8 yuan for every 10 shares and a capital reserve conversion of 4 additional shares for every 10 shares held [2] Group 3 - The actual controllers of Jinkai Biotechnology are Fumin Wang and Lianping Wu, both of whom hold American nationality [3]